Logo-bi
Bioimpacts. 2018;8(3): 153-157.
doi: 10.15171/bi.2018.17
PMID: 30211074
PMCID: PMC6128977
Scopus ID: 85050655722
  Abstract View: 3496
  PDF Download: 2208
  Full Text View: 2665

Editorial

Enzyme replacement therapies: what is the best option?

Azam Safary 1,2 ORCID logo, Mostafa Akbarzadeh Khiavi 3,2 ORCID logo, Rahimeh Mousavi 2, Jaleh Barar 2,4 ORCID logo, Mohammad A Rafi 5*

1 Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
3 Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
5 Department of Neurology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvanian 19107, USA
*Corresponding Author: Email: mohammad.rafi@jefferson.edu

Abstract

Despite many beneficial outcomes of the conventional enzyme replacement therapy (ERT), several limitations such as the high-cost of the treatment and various inadvertent side effects including the occurrence of an immunological response against the infused enzyme and development of resistance to enzymes persist. These issues may limit the desired therapeutic outcomes of a majority of the lysosomal storage diseases (LSDs). Furthermore, the biodistribution of the recombinant enzymes into the target cells within the central nervous system (CNS), bone, cartilage, cornea, and heart still remain unresolved. All these shortcomings necessitate the development of more effective diagnosis and treatment modalities against LSDs. Taken all, maximizing the therapeutic response with minimal undesired side effects might be attainable by the development of targeted enzyme delivery systems (EDSs) as a promising alternative to the LSDs treatments, including different types of mucopolysaccharidoses (MPSs) as well as Fabry, Krabbe, Gaucher and Pompe diseases.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 3492

Your browser does not support the canvas element.


PDF Download: 2208

Your browser does not support the canvas element.


Full Text View: 2665

Your browser does not support the canvas element.

Submitted: 21 Jun 2018
Accepted: 02 Jul 2018
ePublished: 07 Jul 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)